MISSISSAUGA, Ontario, Aug. 18, 2011 /PRNewswire/ — Valeant
Pharmaceuticals International, Inc. (NYSE:
VRX and TSX: VRX) announced that Michael Van Every has resigned
from Valeant’s Board of Directors due to health reasons.
“We want to thank Michael for his many years of service to the
Company, first at Biovail and then, following the merger of Biovail
and Valeant, as part of the new Valeant Board,” stated J. Michael
Pearson, chairman and chief executive officer. “Michael’s
accounting expertise was a tremendous asset to Company and brought
a much needed stability to the financial organization during his
tenure as Head of the Finance and Audit Committee. Michael’s
counsel will be missed and we wish him well in his recovery.”
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of neurology, dermatology and branded
generics. More information about Valeant Pharmaceuticals
International, Inc. can be found at www.valeant.com.
Laurie W. Little